Main Article Content


The aim of this study was to analyze the effects of ethanol extract of sambiloto (Andrographis paniculata) on fatty liver percentage, serum glutamic oxaloacetic transaminase (SGOT) level and lipid profile of wistar strain white rat exposed to high fat diet. The study used randomized post test only control group design. Total sample was 50 male wistar strain rats (Rattus norvegicus) divided randomly into 5 groups (randomization). The normality test used was Kolmogorov Smirnov test (a=0.05). The homogeneity test used was Levene test (a=0.05). The comparative test was done using Anova test (analysis of variance) (a=0.05) or Brown-Forsythe test (a=0.05). The correlation test was done using Pearson test (a=0.05). The administration of sambiloto ethanol extract with doses of 100, 200 and 400 milligrams (mg)/kilogram (kg) body weight (BW) decreased the percentage of fatty liver (r=-0.950), SGOT (r=-0.964)/SGPT (r=(R=-0.973)/LDL (low-density lipoprotein) (r=-0.960) and increased HDL (high-density lipoprotein) levels (r=-0.923)=0.956) in white rats exposed to a high-fat diet. In conclusion, increased dose of ethanol extract of sambiloto can decrease the percentage of fatty liver, SGOT/SGPT and total cholesterol/TG/LDL and increase HDL level of white rats exposed to high fat diet.


Fatty liver Andrographis paniculata SGOT/SGPT lipid profile

Article Details

How to Cite
Jong, F. H. H., Gunawan, A., Santoso, M. W. A., Anjani, S., Tirthaningsih, N. W., & Basori, A. (2018). Effects of Sambiloto Ethanol Extract on Fatty Liver, SGOT/SGPT Levels and Lipid Profile of Wistar Strain White Rat (Rattus norvegicus) Exposed to High-Fat Diet. Folia Medica Indonesiana, 54(2), 89–95.


  1. Bardi DA, Halabi MF, Hassandarvish P, Rouhollahi E, Paydar M, et al (2014). Andrographis paniculata leaf extract prevents thioacetamide-induced liver cirrhosis in rats. Plos One 9, e109424
  2. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T (2014). Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 7, 221-239
  3. Campana B, Semela D, Heim M, Bernsmeier C (2015). Non-alcoholic fatty liver disease – changing the prevalence of liver cancer? Eur Med J Hepatol 3, 12-18
  4. Chen Y, Varghese Z, Ruan XZ (2014). The molecular pathogenic role of inflammatory stress in dysregu-lation of lipid homeostasis and hepatic steatosis. Genes & Diseases 1, 106-112
  5. Ding L, Li J, Song B, Xiao X, Huang W, et al (2014). Andrographolide prevents high-fat diet-induced obesity in C57BL/6 mice by supressing the sterol regulatory element-binding protein pathway. J Pharmacol Exp Ther 351, 474-483
  6. Jarukamjorn K, Nemoto N (2008). Pharmalogical aspects of andrographis paniculata on health and its major diterpenoid constituent andrographolide. J Health Sci 54, 370-381
  7. Jayakumar T, Hsieh C, Lee J, Sheu J (2013). Experi-mental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid Based Complement Alternat Med
  8. Koh PH, Mokhtar RAM, Iqbal M (2013). Andrographis paniculata ameliorates Carbon Tetrachloride (CCL4)-dependent hepatic damage and toxicity: diminution of oxidative stress. Redox Rep 16, 135-143
  9. Kucera O, Cervinkova Z (2014). Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 20, 8364-8376
  10. Kumar V, Abbas AK, Aster JC (2013). Robbins basic pathology. 9th ed. Philadelphia, Elsevier Saunders
  11. Lund-Katz, Phillips (2010). High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem 51, 183-227
  12. Machado MV, Cortez-pinto H (2014). Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 20, 12956-12980
  13. Mahady SE, George J (2013). The future liver of asia pacific: Fatter and firmer from more fructose and fortune. J Clin Exp Hepatol 3, 106-113
  14. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SPS (2008). Med Res Rev 28, 746-772
  15. Romestaing R, Piquet M, Bedu E, Rouleau V, Dautresme M, et al (2007). Long term highly saturated fat diet does not induce NASH in wistar rats. Int J Nut Metab 4, 4
  16. Takaki A, Kawai D, Yamamoto K (2013). Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 14, 04-28
  17. Vornoli A, Pozzo L, Croce CMD, Gervasi PG, Longo V (2014). Drug metabolism enzymes in a steatotic model of rat treated with a high fat diet and a low dose of streptozotocin. Food Chem T 70, 54-60
  18. World Gastroenterology Organisation (2012). Non-alcoholic fatty liver disease and nonalcoholic steato-hepatitis. World Gastroenterology Organisation Global Guidelines, June 2012